Bujanda, LuisSarasqueta, CristinaLanas, AngelQuintero, EnriqueCubiella, JoaquínHernández, VicentMorillas, Juan D.Perez-Fernández, T.Salas, D.Andreu, MontserratCarballo, F.Bessa i Caserras, XavierPortillo, I.Jover, RodrigoBalaguer Prunés, FrancescCosme, ÁngelCastells Garangou, Antoni2018-05-082018-05-082014-02-040007-0920https://hdl.handle.net/2445/122159Background: We aimed to evaluate whether oral anticoagulants (OACs) alter faecal immunochemical test (FIT) performance in average-risk colorectal cancer (CRC) screening. Methods: Individuals aged 50-69 years were invited to receive one FIT sample (cutoff 75 ng ml-1) between November 2008 and June 2011. Results: Faecal immunochemical test was positive in 9.3% (21 out of 224) of users of OAC and 6.2% (365 out of 5821) of non-users (P-trend ¼ 0.07). The positive predictive value (PPV) for advanced neoplasia (AN) in non-users was 50.4% vs 47.6% in users (odds ratio, 0.70; 95% CI, 0.3-1.8; P ¼ 0.5). The PPV for AN in OAC more antiplatelets (aspirin or clopidogrel) was 75% (odds ratio, 2; 95% CI, 0.4-10.8; P ¼ 0.4). Conclusions: Oral anticoagulant did not significantly modify the PPV for AN in this population-based colorectal screening program. The detection rate of advanced adenoma was higher in the combination OAC more antiplatelets.4 p.application/pdfengcc-by-nc-sa (c) Bujanda, Luis et al., 2014http://creativecommons.org/licenses/by-nc-sa/3.0/esCàncer colorectalAnticoagulants (Medicina)ImmunoquímicaColonoscòpiaEstudi de casosColorectal cancerAnticoagulants (Medicine)ImmunochemistryColonoscopyCase studiesinfo:eu-repo/semantics/article6448732018-05-08info:eu-repo/semantics/openAccess24496455